Zoccali C, Abramowicz D, Cannata-Andia JB et al (2008) European best practice guidelines; European renal best practice European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrol Dial Transplant 23:2162–2166

Article  PubMed  Google Scholar 

McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, Drüeke TB, Finkelstein FO, Fishbane S, Ganz T, MacDougall IC (2012) Kidney disease: improving global outcomes (KDIGO) anemia work KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Inter Suppl 2:279–335

Google Scholar 

Locatelli F, Bárány P, Covic A, for ERA-EDTA ERBP Advisory Board et al (2013) Kidney disease: improving global outcomes guidelines on anemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant 28(6):1346–1359

Article  CAS  PubMed  Google Scholar 

Babitt JL, Eisenga MF, Haase VH, for the Conference Participants et al (2021) Controversies in optimal anemia management: conclusions from a kidney disease: improving global outcomes (KDIGO) conference. Kidney Int 99(6):1280–1295

Article  PubMed  Google Scholar 

Ku E, Del Vecchio L, Eckardt KU et al (2023) Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. https://doi.org/10.1016/j.kint.2023.05.009. (PMID: 37236424)

Article  PubMed  Google Scholar 

Takkavatakarn K, Thammathiwat T, Phannajit J et al (2023) The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis. Clin Kidney J 16:845–858

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minutolo R, Liberti ME, Simeon V et al (2023) Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials. Clin Kidney J. https://doi.org/10.1093/ckj/sfad143

Article  PubMed  PubMed Central  Google Scholar 

Chen J, Shou X, Xu Y et al (2023) A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. Aging 15:2237–2274

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Cheng Q, Wang J, Zhao X, Zhu S (2021) Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anemia of chronic kidney disease: a meta-analysis including 13,146 patients. J Clin Pharm Ther 46(4):999–1009

Article  CAS  PubMed  Google Scholar 

Zheng Q, Yang H, Sun L et al (2020) Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis. Pharmacol Res 159:105020

Article  CAS  PubMed  Google Scholar 

Chen D, Niu Y, Liu F et al (2023) Safety of Hif prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. Front Pharmacol. https://doi.org/10.3389/fphar.2023.1163908

Article  PubMed  PubMed Central  Google Scholar 

Natale P, Palmer SC, Jaure A et al (2022) Hypoxia-inducible factor stabilisers for the anemia of chronic kidney disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013751.pub2

Article  PubMed  PubMed Central  Google Scholar 

Zheng Q, Wang Y, Yang H et al (2023) Cardiac and kidney adverse effects of HIF prolyl-hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: a systematic review and meta-analysis. Am J Kidney Dis 81(4):434–445

Article  CAS  PubMed  Google Scholar 

Abdelazeem B, Abbas KS, Shehata J et al (2021) The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials. Ann Transl Med 9(23):1714

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou YP, Mao XY, Wang C et al (2022) Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. J Formos Med Assoc 121(2):529–538

Article  CAS  PubMed  Google Scholar 

Barratt J, Dellanna F, Portoles J et al (2023) Safety of roxadustat versus erythropoiesis-stimulating agents in patients with anemia of non-dialysis-dependent or incident-to-dialysis chronic kidney disease: pooled analysis of four phase 3 studies. Adv Ther 40(4):1546–1559

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agarwal R, Anand S, Eckardt KU et al (2022) Overall adverse event profile of vadadustat versus darbepoetin alfa for the treatment of anemia associated with chronic kidney disease in phase 3 trials. Am J Nephrol 53(10):701–710

Article  CAS  PubMed  Google Scholar 

Sarnak MJ, Agarwal R, Boudville N et al (2023) Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant 38(10):2358–2367

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winkelmayer WC, Arnold S, Burke SK et al (2023) Safety endpoints with vadadustat versus darbepoetin alfa in patients with non-dialysis-dependent CKD: a post hoc regional analysis of the PRO2TECT randomized clinical trial of ESA-Naïve patients. Kidney Med 5(7):100666

Article  PubMed  PubMed Central  Google Scholar 

Haase VH (2011) Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl 2021(11):8–25

Google Scholar 

Provenzano R, Besarab A, Wright S et al (2016) Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67:912–924

Article  CAS  PubMed  Google Scholar 

Fishbane S, Malieckal DA, Ng JH (2023) Hypoxia-inducible factor stabilizers: 27,228 patients studied, yet a role still undefined. Clin Kidney J 16(5):776–779

Article  PubMed  PubMed Central  Google Scholar 

Gupta N, Zhao YY, Evans CE (2019) The stimulation of thrombosis by hypoxia. Thromb Res 181:77–83

Article  CAS  PubMed  Google Scholar 

Fishbane S, Pollock CA, El-Shahawy M et al (2022) Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol 33(4):850–866

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burmakin M, Fasching A, Kobayashi H et al (2021) Pharmacological HIF-PHD inhibition reduces renovascular resistance and increases glomerular filtration by stimulating nitric oxide generation. Acta Physiol (Oxf) 233:e13668

Article  CAS  PubMed  Google Scholar 

Yu J, Wang S, Shi W et al (2021) Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS. JCI Insight 6:e133690

Article  PubMed  PubMed Central  Google Scholar 

Chertow GM, Pergola PE, Farag YMK et al (2021) Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med 384:1589–1600

Article  CAS  PubMed  Google Scholar 

Singh AK, Carroll K, McMurray JJV et al (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 385:2313–2324

Article  CAS  PubMed  Google Scholar 

Fishbane S, El-Shahawy MA et al (2021) Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol 32(3):737–755

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA (2021) Roxadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients not on Dialysis and on Dialysis. FDA Presentation: Cardiovascular and Renal Drugs Advisory Committee Meeting. Available at: https://www.fda.gov/media/150756/download. Accessed 02 Aug 2023

Evrenzo: EPAR - Product information https://www.ema.europa.eu/documents/product-information/evrenzo-epar-product-information_en.pdf. Accessed 02 Aug 2023

Barben M, Samardzija M, Grimm C (2018) The role of hypoxia, hypoxia-inducible factor (HIF), and VEGF in retinal angiomatous proliferation. Adv Exp Med Biol 1074:177–183

Article  CAS  PubMed  Google Scholar 

Zhang D, Lv FL, Wang GH (2018) Effects of HIF-1alpha on diabetic retinopathy angiogenesis and VEGF expression. Eur Rev Med Pharmacol Sci 22:5071–5076

CAS  PubMed  Google Scholar 

Akizawa T, Nangaku M, Yonekawa T et al (2020) Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol 15(8):1155–1165

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sepah YJ, Nguyen QD, Yamaguchi Y et al (2022) Two phase 3 studies on ophthalmologic effects of roxadustat versus darbepoetin. Kidney Int Rep 7:763–775

Article  PubMed  PubMed Central  Google Scholar 

Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M (2020) Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD Patients with anemia on hemodialysis in Japan. J Am Soc Nephrol 31(7):1628–1639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minutolo R, Locat